Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

PsychAD studies map molecular mechanisms across major brain disorders

23

Sep 2026

PsychAD studies map molecular mechanisms across major brain disorders

Research led by Mount Sinai scientists within the PsychAD Consortium, a large-scale, multidisciplinary initiative launched in 2019 with support from the National Institute on Aging (NIA), is featured in a landmark collection of nine papers published across the Nature family of journals that maps the molecular mechanisms underlying Alzheimer's disease, Parkinson's disease, schizophrenia, and other brain disorders.

Menopause leaves a blood protein signature linked to brain aging and Alzheimer’s risk

23

Sep 2026

Menopause leaves a blood protein signature linked to brain aging and Alzheimer’s risk

Researchers identified a 16-protein blood signature associated with menopause that tracked more strongly with reproductive hormones than chronological age and was largely replicated in an independent UK Biobank cohort. Higher menopause proteomic scores were also associated with less favorable proteomic aging estimates and poorer cognitive outcomes in older women, including incident Alzheimer’s dementia, although the observational evidence does not establish causality.

A child's gut microbiome may offer early clues to type 1 diabetes risk

23

Sep 2026

A child's gut microbiome may offer early clues to type 1 diabetes risk

Researchers tracking 887 children at high genetic risk of type 1 diabetes identified three distinct patterns of gut microbiome maturation during early childhood. One pattern was associated with substantially higher risk of islet autoantibody seroconversion or type 1 diabetes, while host genetic background altered the risk associated with another pattern.

A chemical used in BPA-free products may have a connection to diabetes control

23

Sep 2026

A chemical used in BPA-free products may have a connection to diabetes control

In adults with type 2 diabetes receiving oral glucose-lowering therapy, higher plasma BPS concentrations were associated with higher HbA1c after accounting for demographic factors, medication adherence, and diet, whereas BPA was not associated with HbA1c. The BPS association was modest and no longer statistically significant after further adjustment for BPA, BMI, and physical fitness, supporting the need for larger studies to determine whether reducing exposure could improve glycemic control.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.